LFSTNasdaqServices-Health ServicesFiscal year ends December 31
LifeStance Health Group, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$11.77+0.03 (+0.26%)
Close on Oct 19, 2026
- Market cap
- $4.56B
- P/E (TTM)
- 90.5
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Operating margin
1.7%
Net margin
0.7%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +13.9% | +18.3% | – | – | |
| Free cash flow | +28.4% | – | – | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | 0.7% | |
| Return on assets | – | – | 0.4% | |
| Current ratio | – | 1.00 | 1.65 | |
| Debt to equity | – | 0.37 | 0.18 | |
| Net debt to EBITDA | – | – | 0.48× | |
| Interest coverage | – | – | 2.1× | |
| Capex to revenue | – | – | 2.5% | |
| Diluted shares | – | – | 391M |
Where the cash went
Fiscal 2021 to 2025, five years combined
LifeStance Health generated $332.50M from operations and spent $271.96M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$332.50M
Used
$271.96M
Capital expenditure$271.96M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin0.7%
×Asset turnover0.66×
×Equity multiplier1.46×
=Return on equity, FY20250.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 0.7% | 0.66× | 1.46× | 0.7% |
| FY2024 | -4.6% | 0.59× | 1.47× | -4.0% |
| FY2023 | -17.6% | 0.49× | 1.45× | -12.6% |
| FY2022 | -25.1% | 0.42× | 1.34× | -14.1% |
| FY2021 | -46.0% | 0.38× | 1.38× | -24.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
7of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$9.66M
- Cash generatingOperating cash flow above zero$146.15M
- Return on assets improvedROA up on the prior year-2.7% → 0.5%
- Earnings backed by cashOperating cash flow above net income$146.15M vs $9.66M
- Less leverageLong-term debt to assets fell13.2% → 12.1%
- Better liquidityCurrent ratio rose1.37 → 1.65
- No dilutionShare count did not rise379M → 391M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.59 → 0.67